Deal Watch: Taking Care Of Business Before J.P. Morgan
Executive Summary
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
You may also be interested in...
US Smoking Cessation Options Could Expand Behind Achieve Life’s Cytisinicline Studies
Achieved Life would seek approval as Rx smoking cessation drug, but ingredient has history of safety and efficacy available OTC in other countries, says lead researcher in study published in Journal of the American Medical Association.
Homeopathic Dissolvable Strip Firm Shut Down By FTC Will Relaunch After Settling
"It's pretty agonizing now. Our plan is to settle with them as fast as possible and move forward," says Jason Cardiff of Redwood Scientific Technologies in Upland, Calif. FTC alleges firm made unsubstantiated claims for dissolvable film strips for smoking cessation, weight loss and sexual performance; billed customers for unauthorized sales; made "abusive telemarketing through robocalls"; and stated false earnings claims to attract multilevel marketing distributors.
Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech
Momenta will invest in three novel drugs and end development of all but two late-stage biosimilars under a new business strategy. The company is reducing its workforce by 50%, or about 110 employees.